Oncolytics Biotech (ONCY) CFO buys 12,000 shares in open market

Rhea-AI Filing Summary

Oncolytics Biotech Inc. filed a Form 4 showing that its Chief Financial Officer, Kirk Look, made an open-market purchase of company stock. On February 12, 2026, he bought 12,000 common shares at a price of $0.842 per share. After this transaction, he directly beneficially owned 287,515 common shares of Oncolytics Biotech. The filing classifies this as a direct ownership position, reflecting additional personal investment by the company’s senior financial officer.

Insider Trade Summary

Net Buyer: 12,000 shares ($10,104)

Net Buy 1 txn

Insider Look Kirk

Role Chief Financial Officer

Bought 12,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	12,000	$0.842	$10K

Holdings After Transaction: Common Shares — 287,515 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Look Kirk

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/12/2026		P		12,000	A	$0.842	287,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kirk Look	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oncolytics Biotech (ONCY) report in this Form 4?

Oncolytics Biotech reported that its CFO, Kirk Look, purchased 12,000 common shares. The open-market buy occurred on February 12, 2026, at $0.842 per share, increasing his directly held stake to 287,515 common shares in the company.

Who is the insider involved in the latest Oncolytics Biotech (ONCY) Form 4 filing?

The insider is Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc. He is listed as an officer, not a director or 10% owner, and reported a direct open-market purchase of 12,000 common shares, bringing his direct holdings to 287,515 shares.

How many Oncolytics Biotech (ONCY) shares did the CFO buy and at what price?

The CFO, Kirk Look, bought 12,000 Oncolytics Biotech common shares. The transaction was an open-market purchase at a price of $0.842 per share on February 12, 2026, as disclosed in the Form 4 insider trading report.

What is Kirk Look’s total direct share ownership in Oncolytics Biotech (ONCY) after this trade?

After the reported transaction, CFO Kirk Look directly owns 287,515 common shares of Oncolytics Biotech. This total reflects his holdings immediately following the February 12, 2026 open-market purchase of 12,000 additional common shares at $0.842 per share.

Is the Oncolytics Biotech (ONCY) CFO’s recent share transaction a purchase or a sale?

The transaction is a purchase by the CFO of Oncolytics Biotech. The Form 4 lists transaction code “P,” indicating an open-market or private purchase of 12,000 common shares at $0.842 each on February 12, 2026, increasing his direct stake.